#METABOLOMICS WORKBENCH lixinwei_20240923_193010 DATATRACK_ID:5215 STUDY_ID:ST003505 ANALYSIS_ID:AN005753 PROJECT_ID:PR002151
VERSION             	1
CREATED_ON             	September 30, 2024, 9:23 am
#PROJECT
PR:PROJECT_TITLE                 	Uncovering the de novo synthesis of polyamines in gut microbiome using stable
PR:PROJECT_TITLE                 	isotope resolved metabolomics
PR:PROJECT_TYPE                  	metabolomics
PR:PROJECT_SUMMARY               	Using 13C-inulin as a tracer, we tracked the biosynthesis of polyamines in the
PR:PROJECT_SUMMARY               	human and mouse fecal microbiome. Additionally, single-strain SIRM analyses was
PR:PROJECT_SUMMARY               	used to explore functional gut microbes. Liquid chromatography-high resolution
PR:PROJECT_SUMMARY               	mass spectrometry analysis revealed distinct 13C enrichment profiles for
PR:PROJECT_SUMMARY               	polyamines. SIRM analyses were performed using a Q-Exactive HF mass
PR:PROJECT_SUMMARY               	spectrometer, equipped with an Ion Max API source and a HESI II probe, and were
PR:PROJECT_SUMMARY               	coupled to a Dionex UltiMate 3000 UHPLC system (Thermo Fisher Scientific). The
PR:PROJECT_SUMMARY               	findings revealed a novel de novo SPD biosynthesis pathway in the human gut
PR:PROJECT_SUMMARY               	microbiome, and Bacteroides (including B.fragilis and B.thetaiotaomicron)
PR:PROJECT_SUMMARY               	contributed to the biosynthesis of polyamines, underscoring the importance of
PR:PROJECT_SUMMARY               	polyamine bioanalysis in aligning gut microbial functions to host intestinal
PR:PROJECT_SUMMARY               	health.
PR:INSTITUTE                     	Soochow University
PR:LAST_NAME                     	li
PR:FIRST_NAME                    	xinwei
PR:ADDRESS                       	199 Renai Road, Xietang Street, Suzhou, Suzhou, Jiangsu Province, 215031, China
PR:EMAIL                         	lxw9911117@163.com
PR:PHONE                         	19971871675
#STUDY
ST:STUDY_TITLE                   	Investigation of polyamine biosynthesis and metabolism in gut microbiome by
ST:STUDY_TITLE                   	stale isotope resolved metabolomics
ST:STUDY_SUMMARY                 	Polyamines are important gut microbial metabolites known to affect host organs,
ST:STUDY_SUMMARY                 	yet the mechanisms behind their microbial production remain poorly understood.
ST:STUDY_SUMMARY                 	In this study, we used a stable isotope-resolved metabolomic (SIRM) approach to
ST:STUDY_SUMMARY                 	track polyamine biosynthesis in the fecal microbiome. Viable microbial cells
ST:STUDY_SUMMARY                 	were extracted from fresh human and mouse feces and incubated anaerobically with
ST:STUDY_SUMMARY                 	13C-labeled inulin (tracer). Liquid chromatography-high resolution mass
ST:STUDY_SUMMARY                 	spectrometry analysis revealed distinct 13C enrichment profiles for spermidine
ST:STUDY_SUMMARY                 	(SPD) and putrescine (PUT), with the arginine-agmatine-SPD pathway predominating
ST:STUDY_SUMMARY                 	over the well acknowledged spermidine synthase pathway (PUT aminopropylation)
ST:STUDY_SUMMARY                 	for SPD biosynthesis. Furthermore, significant species differences were observed
ST:STUDY_SUMMARY                 	in the 13C enrichments of polyamines and related metabolites between the human
ST:STUDY_SUMMARY                 	and mouse microbiome. Further investigations using single-strain SIRM analyses
ST:STUDY_SUMMARY                 	(Bacteroides) identified the key microbial genes and gut microbes responsible
ST:STUDY_SUMMARY                 	for the polyamine biosynthesis. Taken together, this study expands our
ST:STUDY_SUMMARY                 	understanding of polyamine biosynthesis in the gut microbiome and will
ST:STUDY_SUMMARY                 	facilitate the development of precision therapies to target polyamine-associated
ST:STUDY_SUMMARY                 	diseases.
ST:INSTITUTE                     	Soochow University
ST:LAST_NAME                     	xinwei
ST:FIRST_NAME                    	li
ST:ADDRESS                       	School of Pharmacy, Soochow University 1113
ST:EMAIL                         	lxw9911117@163.com
ST:PHONE                         	19971871675
#SUBJECT
SU:SUBJECT_TYPE                  	Bacteria
SU:SUBJECT_SPECIES               	Human (Intestinal bacteria); Mouse (Intestinal bacteria); Bacteroides
SU:SUBJECT_SPECIES               	(B.fragilis and B.thetaiotaomicron)
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	A1_1	Pos_13D_1	Sample source:Human feces | Treatment Condition:HILIC-HRMS	RAW_FILE_NAME=Pos_13D_1
SUBJECT_SAMPLE_FACTORS           	A1_1	Pos_13D_2	Sample source:Human feces | Treatment Condition:HILIC-HRMS	RAW_FILE_NAME=Pos_13D_2
SUBJECT_SAMPLE_FACTORS           	A1_1	Pos_13D_3	Sample source:Human feces | Treatment Condition:HILIC-HRMS	RAW_FILE_NAME=Pos_13D_3
SUBJECT_SAMPLE_FACTORS           	A1_1	NGE_D_13C_1	Sample source:Human feces | Treatment Condition:HILIC-HRMS	RAW_FILE_NAME=NGE_D_13C_1
SUBJECT_SAMPLE_FACTORS           	A1_1	NGE_D_13C_2	Sample source:Human feces | Treatment Condition:HILIC-HRMS	RAW_FILE_NAME=NGE_D_13C_2
SUBJECT_SAMPLE_FACTORS           	A1_1	NGE_D_13C_3	Sample source:Human feces | Treatment Condition:HILIC-HRMS	RAW_FILE_NAME=NGE_D_13C_3
SUBJECT_SAMPLE_FACTORS           	A1_2	Hcell1	Sample source:Human feces | Treatment Condition:Fmoc-derivatization-LC-HRMS	RAW_FILE_NAME=Hcell1
SUBJECT_SAMPLE_FACTORS           	A1_2	Hcell2	Sample source:Human feces | Treatment Condition:Fmoc-derivatization-LC-HRMS	RAW_FILE_NAME=Hcell2
SUBJECT_SAMPLE_FACTORS           	A1_2	Hcell3	Sample source:Human feces | Treatment Condition:Fmoc-derivatization-LC-HRMS	RAW_FILE_NAME=Hcell3
SUBJECT_SAMPLE_FACTORS           	A2_2	C57cell1	Sample source:mouse feces | Treatment Condition:Fmoc-derivatization-LC-HRMS	RAW_FILE_NAME=C57cell1
SUBJECT_SAMPLE_FACTORS           	A2_2	C57cell2	Sample source:mouse feces | Treatment Condition:Fmoc-derivatization-LC-HRMS	RAW_FILE_NAME=C57cell2
SUBJECT_SAMPLE_FACTORS           	A2_2	C57cell3	Sample source:mouse feces | Treatment Condition:Fmoc-derivatization-LC-HRMS	RAW_FILE_NAME=C57cell3
SUBJECT_SAMPLE_FACTORS           	A3_1	T1P-pos	Sample source:Bacteroides thetaiotaomicron cells | Treatment Condition:HILIC-HRMS	RAW_FILE_NAME=T1P-pos
SUBJECT_SAMPLE_FACTORS           	A3_1	T2P-pos	Sample source:Bacteroides thetaiotaomicron cells | Treatment Condition:HILIC-HRMS	RAW_FILE_NAME=T2P-pos
SUBJECT_SAMPLE_FACTORS           	A3_1	T3P-pos	Sample source:Bacteroides thetaiotaomicron cells | Treatment Condition:HILIC-HRMS	RAW_FILE_NAME=T3P-pos
SUBJECT_SAMPLE_FACTORS           	A3_1	F1P-pos	Sample source:Bacteroides fragilis cells | Treatment Condition:HILIC-HRMS	RAW_FILE_NAME=F1P-pos
SUBJECT_SAMPLE_FACTORS           	A3_1	F2P-pos	Sample source:Bacteroides fragilis cells | Treatment Condition:HILIC-HRMS	RAW_FILE_NAME=F2P-pos
SUBJECT_SAMPLE_FACTORS           	A3_1	F3P-pos	Sample source:Bacteroides fragilis cells | Treatment Condition:HILIC-HRMS	RAW_FILE_NAME=F3P-pos
SUBJECT_SAMPLE_FACTORS           	A3_2	XBPC18_13C-T1C-pos	Sample source:Bacteroides thetaiotaomicron cells | Treatment Condition:Fmoc-derivatization-LC-HRMS	RAW_FILE_NAME=XBPC18_13C-T1C-pos
SUBJECT_SAMPLE_FACTORS           	A3_2	XBPC18_13C-T2C-pos	Sample source:Bacteroides thetaiotaomicron cells | Treatment Condition:Fmoc-derivatization-LC-HRMS	RAW_FILE_NAME=XBPC18_13C-T2C-pos
SUBJECT_SAMPLE_FACTORS           	A3_2	XBPC18_13C-T3C-pos	Sample source:Bacteroides thetaiotaomicron cells | Treatment Condition:Fmoc-derivatization-LC-HRMS	RAW_FILE_NAME=XBPC18_13C-T3C-pos
SUBJECT_SAMPLE_FACTORS           	A3_2	XBPC18_13C-F1C-pos	Sample source:Bacteroides fragilis cells | Treatment Condition:Fmoc-derivatization-LC-HRMS	RAW_FILE_NAME=XBPC18_13C-F1C-pos
SUBJECT_SAMPLE_FACTORS           	A3_2	XBPC18_13C-F2C-pos	Sample source:Bacteroides fragilis cells | Treatment Condition:Fmoc-derivatization-LC-HRMS	RAW_FILE_NAME=XBPC18_13C-F2C-pos
SUBJECT_SAMPLE_FACTORS           	A3_2	XBPC18_13C-F3C-pos	Sample source:Bacteroides fragilis cells | Treatment Condition:Fmoc-derivatization-LC-HRMS	RAW_FILE_NAME=XBPC18_13C-F3C-pos
#COLLECTION
CO:COLLECTION_SUMMARY            	A fraction of the fecal sample was collected fresh in its native state in a
CO:COLLECTION_SUMMARY            	sterile screw-cap container. The samples were quickly transferred to an
CO:COLLECTION_SUMMARY            	anaerobic glove bag to ensure fecal microbiome vitality. The fresh fecal samples
CO:COLLECTION_SUMMARY            	were dissolved in the culture media and processed with a glass rods to suspend
CO:COLLECTION_SUMMARY            	the microorganisms and particles. Then, the suspensions were transferred to an
CO:COLLECTION_SUMMARY            	anaerobic tube and subjected to low-speed centrifugation (600 rpm, 10 min) to
CO:COLLECTION_SUMMARY            	remove larger particles of undigested material. The supernatants were then
CO:COLLECTION_SUMMARY            	collected and centrifuged at 3,000 rpm for 10 min to pellet the microbes. After
CO:COLLECTION_SUMMARY            	washing the precipitated microorganisms using culture medium, the fecal
CO:COLLECTION_SUMMARY            	microbial cells were collected by centrifugation at 3000 rpm for 10 min.
CO:SAMPLE_TYPE                   	Feces (including human and mouse); Bacteroides (including B.fragilis and
CO:SAMPLE_TYPE                   	B.thetaiotaomicron)
#TREATMENT
TR:TREATMENT_SUMMARY             	13C-Inulin was added to each tube aseptically to achieve a final concentration
TR:TREATMENT_SUMMARY             	of 2 g/L inulin. After incubating at 37ºC for 24 h, the samples were
TR:TREATMENT_SUMMARY             	centrifuged and washed with fresh culture medium and centrifuged to collect the
TR:TREATMENT_SUMMARY             	microbial cells for further analysis.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	For the analysis of polyamines, the microbial cells were quenched immediately
SP:SAMPLEPREP_SUMMARY            	after collection using 200 μL of acetonitrile containing 0.2% formic acid. To
SP:SAMPLEPREP_SUMMARY            	each 50 μL aliquot of the sample solution, 50 μL of carbonic acid buffer (0.5
SP:SAMPLEPREP_SUMMARY            	M, pH 10.2) was added, followed by 50 μL of 5 mM Fmoc-OSu solution in
SP:SAMPLEPREP_SUMMARY            	acetonitrile. The mixture was shaken and incubated at room temperature for 15
SP:SAMPLEPREP_SUMMARY            	min. The derivatization reaction was quenched with 20 μL of formic acid, and
SP:SAMPLEPREP_SUMMARY            	the sample was extracted with 500 μL of ethyl acetate. After vortexing for 2
SP:SAMPLEPREP_SUMMARY            	min, the sample was centrifuged and the organic phase was collected and dried
SP:SAMPLEPREP_SUMMARY            	under a nitrogen stream. The samples were stored at −80ºC and dissolved in
SP:SAMPLEPREP_SUMMARY            	acetonitrile: water (9:1, v/v) before analysis. For the untargeted metabolomic
SP:SAMPLEPREP_SUMMARY            	analysis (polar metabolites), the microbial cells were quenched using 450 μL
SP:SAMPLEPREP_SUMMARY            	cold methanol immediately after collection. 5 mL of methyl tert-butyl ether was
SP:SAMPLEPREP_SUMMARY            	added to each tube, and phase separation was then induced by adding 1.25 mL of
SP:SAMPLEPREP_SUMMARY            	deionized water. The samples were then vortexed briefly and centrifuged. Polar
SP:SAMPLEPREP_SUMMARY            	fractions were collected into clean tubes and lyophilized. The dried powder was
SP:SAMPLEPREP_SUMMARY            	stored at −80ºC and dissolved in methanol: water (8:2, v/v) before analysis.
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_SUMMARY        	Fmoc-derivatization-LC-HRMS
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Thermo Q-Exactive HF
CH:COLUMN_NAME                   	Agela Technologies Venusil XBP C18 column (50 x 2.1 mm, 5 μm)
CH:SOLVENT_A                     	100% Water; 0.1% Formic acid
CH:SOLVENT_B                     	100% Acetonitrile
CH:FLOW_GRADIENT                 	0–10 min, linear gradient from 10% to 90% B; 10–14 min, hold at 90% B;
CH:FLOW_GRADIENT                 	14–14.5 min, linear gradient to 10% B; 14.5–20 min, hold at 10% B; and stop
CH:FLOW_GRADIENT                 	running at 32 min.
CH:FLOW_RATE                     	200 μL/min
CH:COLUMN_TEMPERATURE            	40˚C
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	Thermo Q-Exactive HF
MS:INSTRUMENT_TYPE               	Q Exactive HF
MS:MS_TYPE                       	API
MS:ION_MODE                      	POSITIVE
MS:MS_COMMENTS                   	The high resolution mass spectrometer was operated in positive mode with the
MS:MS_COMMENTS                   	spray voltage set to 4.0 kV, the heated capillary was held at 350 °C, and the
MS:MS_COMMENTS                   	HESI probe was set at 325 °C. The sheath gas flow was set as 45 units, the
MS:MS_COMMENTS                   	auxiliary gas flow was set as 10 units, and the sweep gas flow was set to 1
MS:MS_COMMENTS                   	unit. The MS data acquisition was performed in the range of 75–1000 m/z, with
MS:MS_COMMENTS                   	the resolution set at 60,000, the AGC targeted at 1e6, and the maximum injection
MS:MS_COMMENTS                   	time was set at 200 ms. The peak areas of the metabolites and their
MS:MS_COMMENTS                   	isotopologues were integrated and exported to Excel via the Thermo Scientific
MS:MS_COMMENTS                   	Xcalibur (version 4.2.47). Fractional 13C metabolite enrichment was obtained
MS:MS_COMMENTS                   	after natural abundance stripping using Escher-Trace
MS:MS_COMMENTS                   	(https://escher-trace.github.io/app/index.html).
MS:MS_RESULTS_FILE               	ST003505_AN005753_Results.txt	UNITS:Peak area	Has m/z:Yes	Has RT:Yes	RT units:Minutes
#END